Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinran Meiyu vs mupirocin for wound healing after FUE hair transplantation
ChiCTR2500113315Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2025
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Xinran Meiyu in androgenetic alopecia (AGA) and Congenital high hairline (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Wound healing rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
Xinran Meiyu
03
Conditions
androgenetic alopecia (AGA)Congenital high hairline
Beyond the preview
Go deeper on ChiCTR2500113315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113315.